Advertisement
Research Article

Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth

  • Keiichi Kondo,

    Affiliation: Department of Adult Oncology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • William Y Kim,

    Affiliation: Department of Adult Oncology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Mirna Lechpammer,

    Affiliation: Department of Pathology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • William G Kaelin Jr mail

    To whom correspondence should be addressed. E-mail: william_kaelin@dfci.harvard.edu

    Affiliations: Department of Adult Oncology, Dana–Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

    X
  • Published: December 22, 2003
  • DOI: 10.1371/journal.pbio.0000083

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

Inhibition of HIF2α Protein Suppresses pVHL-Driven Tumor Growth

Synopsis | published 22 Dec 2003 | PLOS Biology
doi:10.1371/journal.pbio.0000090